All In Biotech

Drug Trial Radar · NCT07531043

Efficacy and Safety of FID 123472 Ophthalmic Solution for Ocular Redness in Adults

A Two-Arm Multicenter Clinical Trial to Investigate Efficacy and Safety of FID123472 Ophthalmic Solution Compared With Vehicle in Adult Subjects With Ocular Redness

Last checked: Nov 19, 2026Latest source record: Oct 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 230 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

230

Planned (sponsor's estimate)

Start

Sep 30, 2026

Primary completion

Feb 2027

Study completion Feb 2027

Sponsor

Lead sponsor
Alcon ResearchIndustry
Sponsor type
Industry
First posted
Apr 15, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy and safety of an investigational ophthalmic solution in adults with ocular redness due to minor eye irritations.

Conditions

  • Ocular Hyperemia

Interventions

  • Apraclonidine Ophthalmic Solution, 0.125% Unit Dose Preservative FreeDrug

    Investigational ophthalmic solution applied topically to the eye in a unit dose preservative free (UDPF) formulation

  • VehicleDrug

    Inactive ingredients of FID 123472 applied topically to the eye as an ophthalmic solution in a unit dose preservative free (UDPF) formulation

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in investigator-assessed ocular redness at 15 minutes post-instillation on Day 1 (Visit 2)Time frame: Baseline (Day 1 pretreatment); 15 minutes post-instillation (Day 1)
  2. Change from baseline in investigator-assessed ocular redness at 840 minutes (14 hours) post-instillation on Day 2 (Visit 3)Time frame: Baseline (Day 1 pretreatment); 840 minutes (14 hours) post-instillation (Day 2)

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • East West Eye Institute

    Los Angeles, California · Recruiting

  • Eye Research Foundation

    Newport Beach, California · Recruiting

  • Kannarr Eye Care LLC

    Pittsburg, Kansas · Not yet recruiting

  • Butchertown Clinical Trials

    Louisville, Kentucky · Not yet recruiting

  • Andover Eye Associates

    Andover, Massachusetts · Not yet recruiting

  • NC Eye Associates, OD, PLLC

    Apex, North Carolina · Not yet recruiting

  • Scott & Christie and Associates, PC

    Cranberry Township, Pennsylvania · Not yet recruiting

  • Advancing Vision Research, LLC

    Smyrna, Tennessee · Not yet recruiting

  • Contact Alcon Call Center for Trial Locations

    Fort Worth, Texas · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.